Press Release

  • Press Release
  • No Likes

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements 150 150 Press Release

• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT,…

read more
  • Press Release
  • No Likes

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI 150 150 Press Release

FREMONT, CA – July 9, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II clinical trials of their medication…

read more
  • Press Release
  • No Likes

ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals 150 150 Press Release

ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment…

read more
  • Press Release
  • No Likes

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M 150 150 Press Release

FREMONT, CA, April 17, 2024 ABVC BioPharma Inc,a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (centra l nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered…

read more
  • Press Release
  • No Likes

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M 150 150 Press Release

FREMONT, CA, April 10, 2024 ABVC BioPharma Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and…

read more
  • Press Release
  • No Likes

BVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
BVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M 150 150 Press Release

FREMONT, CA, March 26, 2024 ABVC BioPharma Inc, a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation…

read more
  • Press Release
  • No Likes

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC’s 23M AiBtl Share Ownership as Hundred Million Dollars
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC’s 23M AiBtl Share Ownership as Hundred Million Dollars 150 150 Press Release

FREMONT, CA, March 21, 2024 ABVC BioPharma Inc, a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl BioPharma Inc. (AIBL), entered into an Agreement…

read more
  • Press Release
  • No Likes

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine 150 150 Press Release

FREMONT, CA, March 19, 2024 ABVC BioPharma Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the…

read more
  • Press Release
  • No Likes

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update 150 150 Press Release

FREMONT, CA, March 14, 2024 ABVC BioPharma Inc, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.…

read more
  • Press Release
  • No Likes

ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars 150 150 Press Release

FREMONT, CA, Feb. 27, 2024 ABVC BioPharma Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination…

read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.